Santa Monica, CALIFORNIA3 Active Studies

Prurigo Nodularis Clinical Trials in Santa Monica, CALIFORNIA

Find 3 actively recruiting prurigo nodularis clinical trials in Santa Monica, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
600
Enrolling

Recruiting Prurigo Nodularis Studies in Santa Monica

About Prurigo Nodularis Clinical Trials in Santa Monica

Prurigo nodularis is a chronic skin condition characterized by intensely itchy, hard lumps on the skin that develop from repeated scratching. It significantly impacts quality of life and sleep. Treatment includes topical therapies, phototherapy, and newer targeted biologics.

There are currently 3 prurigo nodularis clinical trials recruiting participants in Santa Monica, CALIFORNIA. These studies are seeking a combined 600 participants. Research is being sponsored by Incyte Corporation, University of California, Los Angeles, Celldex Therapeutics. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prurigo Nodularis Clinical Trials in Santa Monica — FAQ

Are there prurigo nodularis clinical trials in Santa Monica?

Yes, there are 3 prurigo nodularis clinical trials currently recruiting in Santa Monica, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Santa Monica?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Santa Monica research site will contact you about next steps.

Are clinical trials in Santa Monica free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Santa Monica studies also compensate for your time and travel.

What prurigo nodularis treatments are being tested?

The 3 active trials in Santa Monica are testing new therapies including novel drugs, biologics, and treatment approaches for prurigo nodularis.

Data updated March 2, 2026 from ClinicalTrials.gov